Icon
+91 94997 68112
Login Register

Lastacaft - (0.25%; Solution/Drops, Ophthalmic)

Alcaftadine Allergan
0.25%; Solution/Drops, Ophthalmic
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
 None
Indicated for the prevention of itching associated with allergic conjunctivitis.
Yes
******** (******) ** *** ***** ** **** **** ** **** ****** '*** (*** **, ****) *** *** ************ *********. ****** *** ****** ** ** ****** **** ********** *** ********* **** ******** ***** *** ***** ** ********* *** *** *****. ******* ******** (******) **** ***** **** ** **** *** **** ****** *** *** ************ ********* ***** *** ********** *** ********* **** ******** ** **** *** *** ***** ** ********* *** *** *****. *****, ********* (******) **** ***** * **** ** ** ****** '*** *** *** *********. ****, ********** *** ********* **** *********. ********* ** ********** ********* ***'* ****** ******* ***** *** ********** ** ****** '*** (*** **, ****). **, ** ******** **** ***** ******* **** **** ****** ******* ***** ********** ** ****** '*** (*** **, ****). *****, ***** (******) ****** ***** * **** ** *** *** *********.
Lastacaft Patent 1 Patent 2
******** ******* *******
******** ******* *******
********* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******** *** \ ** **** *, **** ******* **** ******* *** **** *** *** ****
******** ** \ ** *** **, **** ******* **** ******* *** **** *** *** ****
********* ** \ ** ***** *, **** ******* ******** ************ ******* *** **** *** *** ****
  1. *** **, **** : ******** ******** ******** *** ******** ***** *** **** ** **** ****** '*** (*** **, ****).
  2. *** *, **** : ******** *** ******** ***** * **** ******* ******** ** ******** ***** ** ********.
  3. *** **, **** : ********** *** ********* **** ******** ***** *** ***** ** ********* *** *** *****.
  4. *** **, **** : ******** *** ******** ***** * **** ******* ******** ** ******** ***** **** ** **** ****** '*** (*** **, ****).
  5. *** **, **** : ********** *** ********* **** ******** ***** *** ***** ** ********* *** *** *****.
  6. *** *, **** : ******** *** ******** ***** * **** ******* ********* ** ********* ***** **** ** **** ****** '*** (*** **, ****).
  7. *** **, **** : ********** *** ********* **** *********. ********* ** ********** ********* ***'* ****** ******* ***** *** ********** ** ****** '*** (*** **, ****).
  8. *** **, **** : * *** ****** ******** (***** **, ****) ******.
  9. *** **, **** : ***** ****** ******** ******** ***** **'* **** ** ****** ** ******* '*** *** '***
  10. *** *, **** : ******** ***** * **** ******* ***** ****** ** ******* '*** *** '***
  11. *** **, **** : ******* ******** ********* ******** *** *** *** *********. ** ****** **** ***** * **** *** ** *** *******.
  12. *** **, **** : ******* ********* ***** **** *** ** **** **. ******* ******** ******** ***** *** **** ** ******.
  13. *** **, **** : ******** **** ******* **** ************ ** ****** ** '*** *** '***.
  14. *** **, **** : ******** *** ******* ******* ********** **** ************ ** ****** ** '*** *** '***. ** ****** **** **** ** **** **** ** ****** ******* *** **** *** *** **** ********* ** ***** ***********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.